A large long-term study reported that dexrazoxane can protect children’s hearts from lasting chemotherapy damage years after treatment. The findings extend beyond immediate cardiotoxicity endpoints, reflecting survivorship follow-up into young adulthood and providing stronger evidence for when and how clinicians can reduce downstream cardiovascular risk. For pediatric oncology teams, this shifts decision-making from short-horizon toxicity management to sustained organ-sparing strategy. The results also reinforce the role of evidence that tracks patients after active treatment ends, particularly in populations with decades of life ahead. Overall, the dataset positions dexrazoxane as a durability-focused protective intervention—one that may influence survivorship care pathways and future chemotherapy protocols.